AI-driven drug safety platforms seen growing to $5.39 billion by 2030

The market for AI-driven drug safety and pharmacovigilance platforms is projected to rise from $2.59 billion in 2026 to $5.39 billion by 2030, according to The Business Research Company. Growth is being driven by stricter reporting rules, more adverse event reports and wider use of AI, real-world data and cloud-based monitoring tools.

Why it matters: - AI-driven pharmacovigilance tools are becoming a core part of drug safety monitoring as regulators and drugmakers face more data, more reporting requirements and more pressure to detect safety signals faster. - The shift could improve patient safety, speed compliance work and reduce manual case-processing burdens across the pharmaceutical lifecycle.

What happened: - The Business Research Company released its Artificial Intelligence (AI)-Driven Drug Safety and Pharmacovigilance Platforms Global Market Report 2026 on Sept. 3, 2026. - The report says the market will grow from $2.14 billion in 2025 to $2.59 billion in 2026. - The report projects the market will reach $5.39 billion by 2030, with a 20.2% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region.

The details: - The report ties near-term growth to global mandates on adverse drug reaction reporting, digitization of clinical trial information, expanding pharmacovigilance regulations, higher pharmaceutical research activity and wider use of electronic health records. - Long-term growth is linked to AI integration in drug safety monitoring, broader use of real-world evidence, stricter automated compliance reporting requirements, predictive safety analytics and cloud-based monitoring solutions. - The market is moving toward AI-powered adverse event detection, natural language processing for safety signal extraction, predictive analytics, real-time monitoring using real-world data and automated regulatory safety reporting. - AI-driven drug safety platforms use machine learning, natural language processing and advanced analytics to monitor, evaluate and prevent adverse drug reactions and safety risks. - These platforms analyze clinical, real-world and regulatory data to improve safety signal detection, automate reporting and support compliance. - A sample report is available here. - The full report is available here.

Between the lines: - Rising adverse event reporting is a key demand driver because AI systems can aggregate data from clinical systems, electronic health records and real-world sources faster than manual workflows. - The report cites February 2024 data from the Department of Health Abu Dhabi showing 1,522 adverse drug reaction reports in 2023, a 235% increase from previous years. - More digitized health data and stricter regulatory frameworks are pushing AI tools from optional add-ons toward compliance infrastructure. - The emphasis on market hotspots, TAM analysis and scoring tools suggests vendors are competing in a fast-forming category with room for regional expansion and product differentiation.

What's next: - The market report expects continued adoption of AI in safety monitoring as regulators demand more automated compliance and companies rely more on real-world evidence. - The report says cloud-based solutions, predictive analytics and real-time monitoring will shape the next phase of product development. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspots infographics and updated trend graphics.

The bottom line: - AI is moving pharmacovigilance from retrospective reporting toward faster, data-driven safety surveillance, and the market outlook points to sustained double-digit growth through 2030.